Cargando…

Immunotherapy for non-small cell lung cancers: biomarkers for predicting responses and strategies to overcome resistance

Recent breakthroughs in targeted therapy and immunotherapy have revolutionized the treatment of lung cancer, the leading cause of cancer-related deaths in the United States and worldwide. Here we provide an overview of recent progress in immune checkpoint blockade therapy for treatment of non-small...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pu, Xingxiang, Wu, Lin, Su, Dan, Mao, Weimin, Fang, Bingliang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6225701/ https://www.ncbi.nlm.nih.gov/pubmed/30409126 http://dx.doi.org/10.1186/s12885-018-4990-5

Ejemplares similares

Overcoming immunotherapy resistance in non-small cell lung cancer (NSCLC) - novel approaches and future outlook
por: Horvath, Lena, et al.
Publicado: (2020)

The Immune Landscape of Breast Cancer: Strategies for Overcoming Immunotherapy Resistance
por: Retecki, Kuba, et al.
Publicado: (2021)

Immunotherapy biomarkers 2016: overcoming the barriers
por: Gulley, James L., et al.
Publicado: (2017)

Neoadjuvant Immunotherapy and Non–Small Cell Lung Cancer: A Systematic Review and Meta-analysis of Randomized Controlled Trials
por: Yu, Shaofu, et al.
Publicado: (2023)

MET Inhibitor is Expected to Overcome MET Amplification-Induced Immunotherapy Resistance in Non-Small Cell Lung Cancer
por: Ruan, Ji
Publicado: (2021)

Patient-derived tumor immune microenvironments in patient-derived xenografts of lung cancer
por: Pu, Xingxiang, et al.
Publicado: (2018)

Telomerase-Mediated Strategy for Overcoming Non–Small Cell Lung Cancer Targeted Therapy and Chemotherapy Resistance
por: Mender, Ilgen, et al.
Publicado: (2018)

Strategies to overcome resistance to ALK inhibitors in non-small cell lung cancer: a narrative review
por: Desai, Aakash, et al.
Publicado: (2023)

Modeling strategies to analyse longitudinal biomarker data: An illustration on predicting immunotherapy non-response in non-small cell lung cancer
por: van Delft, Frederik A., et al.
Publicado: (2022)

Biomarkers of immunotherapy in non-small cell lung cancer
por: Wang, Lingling, et al.
Publicado: (2020)

Barriers to overcoming immunotherapy resistance in glioblastoma
por: Gillette, Julia S., et al.
Publicado: (2023)

Therapeutic Strategies for Overcoming Immunotherapy Resistance Mediated by Immunosuppressive Factors of the Glioblastoma Microenvironment
por: Miyazaki, Tsubasa, et al.
Publicado: (2020)

Editorial: Gastrointestinal cancer immunotherapy: from drug resistance mechanisms to overcoming strategies
por: Shi, Tao, et al.
Publicado: (2023)

Immunotherapy resistance in non-small-cell lung cancer: From mechanism to clinical strategies
por: Zhou, Suna, et al.
Publicado: (2023)

T lymphocytes related biomarkers for predicting immunotherapy efficacy in non-small cell lung cancer
por: Wei, Xiaoying, et al.
Publicado: (2021)

Using triple radio-immunotherapy to overcome cancer immunotherapy resistance
por: Zhang, Zengfu, et al.
Publicado: (2023)

Immunotherapy with CAR-Modified T Cells: Toxicities and Overcoming Strategies
por: Sun, Shangjun, et al.
Publicado: (2018)

Recent and Future Strategies to Overcome Resistance to Targeted Therapies and Immunotherapies in Metastatic Colorectal Cancer
por: Dazio, Giulia, et al.
Publicado: (2022)

Editorial: Strategies to overcome tumor evasion and resistance to immunotherapies by targeting immune suppressor cells
por: Saida, Yu, et al.
Publicado: (2023)

Clinical definition of secondary resistance to immunotherapy in non‐small cell lung cancer
por: Huang, Dingzhi, et al.
Publicado: (2023)

Predictive biomarkers in precision medicine and drug development against lung cancer
por: Fang, Bingliang, et al.
Publicado: (2015)

Imaging Biomarkers to Predict and Evaluate the Effectiveness of Immunotherapy in Advanced Non-Small-Cell Lung Cancer
por: Liu, Ying, et al.
Publicado: (2021)

Smart drug delivery systems to overcome drug resistance in cancer immunotherapy
por: Yi, Wenzhe, et al.
Publicado: (2023)

Evolutionary Modeling of Combination Treatment Strategies To Overcome Resistance to Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer
por: Mumenthaler, Shannon M., et al.
Publicado: (2011)

Emerging strategies to overcome resistance to third-generation EGFR inhibitors
por: Shi, Kunyu, et al.
Publicado: (2022)

Insights and Strategies of Melanoma Immunotherapy: Predictive Biomarkers of Response and Resistance and Strategies to Improve Response Rates
por: Seyhan, Attila A., et al.
Publicado: (2022)

Double Guard Efficiency and Safety—Overcoming Resistance to Immunotherapy by Blocking or Stimulating Several Immune Checkpoints in Non-Small Cell Lung Cancer Patients
por: Kalinka, Ewa, et al.
Publicado: (2023)

A small-molecule compound D6 overcomes EGFR-T790M-mediated resistance in non-small cell lung cancer
por: Tang, Xiaolong, et al.
Publicado: (2021)

Current Landscape of Therapeutic Resistance in Lung Cancer and Promising Strategies to Overcome Resistance
por: Ashrafi, Adnin, et al.
Publicado: (2022)

Predicting response to immunotherapy in advanced non-small-cell lung cancer using tumor mutational burden radiomic biomarker
por: He, Bingxi, et al.
Publicado: (2020)

Bcl-2 Inhibition to Overcome Resistance to Chemo- and Immunotherapy
por: García-Aranda, Marilina, et al.
Publicado: (2018)

Drugging the Epigenome: Overcoming Resistance to Targeted and Immunotherapies in Melanoma
por: Hanly, Ailish, et al.
Publicado: (2021)

A new approach to overcoming resistance to immunotherapy: nanotechnology
por: Shao, Jiangbo, et al.
Publicado: (2023)

Emerging Blood-Based Biomarkers for Predicting Response to Checkpoint Immunotherapy in Non-Small-Cell Lung Cancer
por: Li, Shumin, et al.
Publicado: (2020)

The Combination of Radiotherapy With Immunotherapy and Potential Predictive Biomarkers for Treatment of Non-Small Cell Lung Cancer Patients
por: Meng, Lu, et al.
Publicado: (2021)

Soluble Biomarkers with Prognostic and Predictive Value in Advanced Non-Small Cell Lung Cancer Treated with Immunotherapy
por: Honrubia-Peris, Beatriz, et al.
Publicado: (2021)

FGFR inhibitors combined with nab-paclitaxel - A promising strategy to treat non-small cell lung cancer and overcome resistance
por: Ma, Feng, et al.
Publicado: (2023)

Peripheral Blood Biomarkers Associated With Outcome in Non-small Cell Lung Cancer Patients Treated With Nivolumab and Durvalumab Monotherapy
por: Jiang, Meilin, et al.
Publicado: (2020)

Tumor cell p38 inhibition to overcome immunotherapy resistance
por: Luke, Jason J., et al.
Publicado: (2023)

m(6)A regulators as predictive biomarkers for chemotherapy benefit and potential therapeutic targets for overcoming chemotherapy resistance in small-cell lung cancer
por: Zhang, Zhihui, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_n7fp7bn47i6qa1js8372pmbc0i